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Background. The 4 dengue virus serotypes (DENV1–4) and Zika virus (ZIKV) are related mosquito-borne flaviviruses of major 
importance globally. While monoclonal antibodies and plasma from DENV-immune donors can neutralize or enhance ZIKV in 
vitro and in small-animal models, and vice versa, the extent, duration, and significance of cross-reactivity in humans remains un-
known, particularly in flavivirus-endemic regions.
Methods. We studied neutralizing antibodies to ZIKV and DENV1–4 in longitudinal serologic specimens collected through 
3 years after infection from people in Latin America and Asia with laboratory-confirmed DENV infections. We also evaluated neu-
tralizing antibodies to ZIKV and DENV1–4 in patients with Zika through 6 months after infection.
Results. In patients with Zika, the highest neutralizing antibody titers were to ZIKV, with low-level cross-reactivity to DENV1–4 
that was greater in DENV-immune individuals. We found that, in primary and secondary DENV infections, neutralizing antibody 
titers to ZIKV were markedly lower than to the infecting DENV and heterologous DENV serotypes. Cross-neutralization was great-
est in early convalescence, then ZIKV neutralization decreased, remaining at low levels over time.
Conclusions. Patterns of antibody cross-neutralization suggest that ZIKV lies outside the DENV serocomplex. Neutralizing 
antibody titers can distinguish ZIKV from DENV infections when all viruses are analyzed simultaneously. These findings have impli-
cations for understanding natural immunity and vaccines.
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The 4 dengue virus (DENV) serotypes (DENV1–4) and Zika 
virus (ZIKV) are mosquito-borne flaviviruses of global health 
importance. Dengue is the most prevalent arboviral disease 
of humans, with up to 390 million infections annually [1]. 
ZIKV expanded dramatically throughout Latin America in 
2015–2016 [2]. Although the majority of infections are mild or 
asymptomatic, ZIKV infection during pregnancy is linked with 
devastating birth defects, including microcephaly, and with 
Guillain-Barré syndrome in adults [3, 4]. Because of shared 
Aedes mosquito vectors, ZIKV spreads in geographic areas 
where DENV is endemic [5]. Since ZIKV also  circulates in 
Africa and Asia [6, 7], billions of people are at risk of sequential 
or concurrent DENV and ZIKV infections.
The envelope protein (E) is a major target of the human an-
tibody response to flaviviruses. The ectodomain of E comprises 
3 domains (EDI, EDII, and EDIII), with distinct roles in virus 
attachment, entry, and membrane fusion. DENV and ZIKV 
are closely related (approximately 55% E amino acid identity) 
[8–10], giving rise to a high degree of structural and antigenic 
similarity [8, 9]. Therefore, it is not surprising that extensive an-
tibody cross-reactivity is observed.
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In fact, serologic cross-reactivity among flaviviruses has long 
been appreciated and used to categorize flaviviruses into sero-
complexes and subcomplexes [11, 12]. With DENV, cross-re-
active antibodies elicited by the infecting serotype bind and 
neutralize heterologous DENV serotypes, corresponding to a 
transient period of cross-protection or disease attenuation fol-
lowing primary DENV infection. In the absence of subsequent 
DENV infections, the neutralizing antibody (nAb) response 
typically narrows in regions of nonendemicity, conferring long-
term immunity only to the infecting DENV serotype [13, 14]. 
However, cross-reactive nAb responses appear to be maintained 
over time in dengue-endemic regions [15]. Serologic cross-reac-
tivity between DENV and ZIKV has been clearly demonstrated 
[8, 10, 16, 17]. Some monoclonal antibodies (mAbs) derived 
from DENV-immune patients cross-neutralize ZIKV [18] and 
protect against lethal ZIKV challenge in a mouse model [19]. 
Human plasma collected ≤100 days after reverse-transcription 
polymerase chain reaction (RT-PCR)–confirmed DENV in-
fection also binds and cross-neutralizes ZIKV [8]. However, 
late-convalescent-phase plasma from DENV-immune travelers 
does not harbor durable, high levels of cross-neutralizing anti-
bodies against ZIKV [20]. Thus, substantial deficiencies exist 
in our understanding of cross-neutralizing antibody responses 
among individuals with prior DENV exposure, particularly how 
these responses evolve over time and in various transmission 
contexts in flavivirus-endemic countries. Here, we character-
ized the extent of anti-DENV and anti-ZIKV neutralization in 
individuals from Latin America and Asia over months to years 
following molecularly confirmed DENV and ZIKV infections.
METHODS
Ethics Statement
All studies were approved by the relevant institutional review 
boards at the participating institutions (Supplementary Methods).
Study Site and Sample Selection
Nicaragua
Samples were from 2 prospective studies of pediatric dengue and 
Zika in Managua, Nicaragua. In the hospital study (1998–pre-
sent), study enrollment occurs in the Nicaraguan Hospital Infantil 
Manual de Jesús Rivera. Children 6  months to 14  years of age 
suspected of having dengue or Zika (<7 days of illness) are eli-
gible [21]. All suspected dengue and Zika cases are confirmed by 
DENV serotype–specific and ZIKV RT-PCR and serologic meth-
ods [22, 23]. Samples from dengue cases for this study (n = 180) 
were collected at the acute (days 1–6) and convalescent (days 
14–28) phases, as well as 3, 6, 12, and 18 months following pri-
mary and secondary symptomatic DENV infections (DENV1, 
DENV2, and DENV3; Table 1). Primary and secondary dengue 
cases were defined by an Inhibition enzyme-linked immuno-
sorbent assay (ELISA) [24, 25] titer of <2560 or ≥2560, respec-
tively, in the convalescent-phase sample [23]. Samples from the 
14-year ongoing community-based Pediatric Dengue Cohort 
Study (2004–present) included annual healthy blood samples col-
lected 1–3 years following secondary DENV1, DENV2, DENV3, 
and DENV4 infections (n = 42). All samples from dengue cases 
were collected prior to the introduction of ZIKV into Nicaragua 
in 2016. Children with RT-PCR–confirmed Zika from the hospi-
tal-based study [22] included those with (n = 7) and those without 
(n = 10) prior DENV immunity who had samples collected during 
the acute and early convalescent phases and 3 and 6 months after 
ZIKV infection (Table  1). All blood samples were collected in 
5 mM ethylenediaminetetraacetic acid (EDTA), and plasma was 
separated by centrifugation, aliquoted, and stored at −80°C.
Sri Lanka
In a cohort study, archived dried blood spots (DBS) speci-
mens stored at 4°C on protein saver cards from the Sri Lankan 
Pediatric Dengue Vaccine Initiative cohort [26] were processed 
with validated methods as previously described [26, 27]. From 
November 2008 to January 2010, a surveillance study of approx-
imately 800 children ≤12 years of age was conducted by obtain-
ing baseline, 1-year, and 2-year follow-up DBS specimens, 
which were tested for DENV-specific IgG. Children experienc-
ing a febrile illness (temperature ≥38°C for ≤7 days) had blood 
specimens collected at presentation and during the convalescent 
phase, ≥10 days after symptom resolution. Diagnostic RT-PCR 
analysis was performed on acute specimens [26]. The baseline 
DENV serostatus of each child was used to classify subsequent 
RT-PCR–confirmed infection as primary or secondary [26].
In a hospital study, individuals presenting with acute febrile 
illness suspected of dengue, based on the clinical expertise of 
local clinicians, were enrolled. Serum was collected at presen-
tation, and convalescent-phase serum specimens were obtained 
≥10 days later. In hospital cases, the presence of DENV-specific 
IgG in the acute-phase samples (collected 1–5 days after onset of 
symptoms) was used to define primary or secondary cases [27]. 
Only RT-PCR–confirmed cases were used in both these studies.
Thailand
Suspected dengue cases were identified on presentation to 
Khon Kaen Hospital. Patients with acute febrile illness clinically 
suspected to be dengue were enrolled. Only cases that showed 
dengue symptoms confirmed by DENV RT-PCR were included 
in this study. Samples collected during hospitalization were 
considered acute-phase samples. Convalescent-phase sam-
ples were collected at 2–4 weeks and again at 5–7 months. The 
infecting DENV serotype was determined by RT-PCR analysis 
[28]. Secondary DENV infection was classified as a ratio of anti-
DENV immunoglobulin M (IgM) to IgG of <1.8, as measured 
by IgM and IgG capture ELISA [29]. During the acute phase, 
the day of defervescence was defined as day 0, the day before 
as day −1, the day after as day 1, and so on. Blood samples were 
collected in 5 mM EDTA, and plasma was separated by centrif-
ugation, aliquoted, and stored at −80°C.
Cell Culture and Virus Production
Vero-81, C6/36, and U937 cells were cultured as described in 
the Supplementary Methods. At the University of California–
Berkeley, all 4 DENV serotypes (DENV1 N1265-04, DENV2 
N172-06, DENV3 N7236-98, and DENV4 N703-99) and 
ZIKV Nica 1–16 were isolated in Nicaragua and propa-
gated (low passage: 2–3) in C6/36 cells [30]. All viral stocks 
were Mycoplasma free, and viral titers were determined 
by focus-forming assays on Vero cells. At the University of 
North Carolina–Chapel Hill, ZIKV strain H/PF/2013 was 
provided by the Centers for Disease Control and Prevention 
[31]; DENV World Health Organization reference strains 
(DENV1 West Pac 74, DENV2 S-16803, DENV3 CH54389, 
and DENV4 TVP-360) were obtained from Dr R.  Putnak 
(Walter Reed Army Institute of Research). Virus stocks were 
prepared in C6/36 Aedes albopictus cells (ATCC CRL-1660). 
All DENV strains used were passage 4 and ZIKV was passage 
3. At Imperial College London, ZIKV strain PF13/251013–
18 (PF13) from French Polynesia in 2013 was provided by
Dr V.-M. Cao-Lormeau (Institut Louis Malardé). DENV1
(Hawaii), DENV2 (16681), and DENV3 (H87) were gifts from 
the Armed Forces Research Institute of Medical Sciences. 
DENV-4 (1-0093) was isolated from a DENV4-infected pa-
tient. Virus-containing supernatants were collected and 
stored at −80°C. Viral titers were determined by focus-form-
ing assays on Vero cells. All cell lines and virus stocks were 
free from Mycoplasma contamination.
Focus Reduction Neutralization Test (FRNT)
An FRNT was performed at the University of California–
Berkeley, the University of North Carolina–Chapel Hill, and 
Imperial College London, using Vero cells and all 4 DENV sero-
types and ZIKV in parallel (see the Supplementary Methods for 
experimental details, calculation of nAb titers, and quality con-
trol measures).
Antibody-Dependent Enhancement (ADE) Assay
Serially diluted plasma samples were incubated with virus at 
a multiplicity of infection of 2 for 1 hour at 37°C before addi-
tion to U937 cells. After incubation for 2  days (for ZIKV) or 
Table 1. Samples Included in the Study
Study Site, Infecting Virus Participants, No. Immune Status Collection Time Points Samples, No.
Nicaragua
Hospital study
  DENV1 10 5 had primary infection, and 5 had  
secondary infection
Acute phase, convalescent phase, and 3, 6, 
12, and 18 mo
60
  DENV2 10 5 had primary infection, and 5 had  
secondary infection
Acute phase, convalescent phase, and 3, 6, 
12, and 18 mo
60
  DENV3 10 5 had primary infection, and 5 had  
secondary infection
Acute phase, convalescent phase, and 3, 6, 
12, and 18 mo
60
  ZIKV
   Group 1 10 DENV naive Acute phase, convalescent phase, and 3 and 
6 mo
40




  Nonea 5 5
  DENV1 4 Secondary infection 1, 2, and 3 y after infection 12
  DENV2 4 Secondary infection 1, 2, and 3 y after infection 12
  DENV3 3 Secondary infection 1, 2, and 3 y after infection 9
  DENV4 3 Secondary infection 1, 2, and 3 y after infection 9
Sri Lanka
 DENV1 18 10 had primary infection, and 8 had  
secondary infection
Variable: up to 217 d after infection 41
Other DENV serotypes 7 3 had primary infection, and 4 had  
secondary infection
Variable: up to 202 d after infection 16
Thailand
 DENV1 6 Secondary infection Acute phase and convalescent phase (2–4 wk 
and 6 mo)
18
 DENV2 11 Secondary infection Acute phase and convalescent phase (2–4 wk 
and 2 and 6 mo)
51
 DENV3 1 Secondary infection Acute phase and convalescent phase (2–4 wk 
and 6 mo)
3
 DENV4 2 Secondary infection Acute phase and convalescent phase (2–4 wk 
and 6 mo)
6
Abbreviations: DENV, dengue virus; ZIKV, Zika virus.
aSpecimens were negative for ZIKV and DENV.
3 days (for DENV), supernatants were harvested, and viral titers 
were determined by focus-forming assays as described in the 
Supplementary Methods. Fold enhancement was calculated by 
comparison to viral titers in the presence or absence of plasma.
RESULTS
Immune Plasma From ZIKV-Infected Individuals With and Those Without 
Prior DENV Immunity Have High ZIKV nAb Titers
We selected Nicaraguan children from our hospital-based study 
who had RT-PCR–confirmed, symptomatic Zika with (n  =  7) 
or without (n = 10) evidence of prior DENV immunity. All had 
nAb titers against DENV1–4 and ZIKV determined in samples 
collected during the acute and early convalescent phases and 3 
and 6 months after ZIKV infection. First, the assay background 
value was confirmed as undetectable by testing specimens from 
DENV-naive, ZIKV-naive controls (Supplementary Figure  1). 
We found that peak nAb titers against ZIKV following ZIKV 
infection were higher than any 50% focus reduction neutraliza-
tion test titer (FRNT50) to DENV1–4. Interestingly, the magni-
tude of the peak ZIKV nAb response (ie, the FRNT50 during the 
convalescent phase) and the responses in the 3- and 6-month 
follow-up specimens was similar regardless of preexisting DENV 
immunity (Figure  1A, B). ZIKV infection elicited detectable 
cross-neutralization to DENV1–4 at all time points after infec-
tion. As expected, samples from DENV-immune children with 
ZIKV infection exhibited greater neutralization to the 4 DENV 
serotypes than those who were DENV-naive (Figure 1A, B).
DENV Infection Elicits Low but Sustained Cross-neutralizing Antibody 
Responses to ZIKV in Nicaraguan Children
To determine the extent and duration of cross-neutraliza-
tion of ZIKV by DENV-immune plasma, longitudinal samples 
collected at the acute and convalescent phases and 3, 6, 12, and 
18 months after infection from primary and secondary DENV1, 
DENV2, and DENV3 cases (before the introduction of ZIKV 
into Nicaragua) in our hospital study were tested for nAb ac-
tivity against all 4 DENV serotypes (DENV1–4) and ZIKV by the 
FRNT. As expected, plasma from primary dengue cases showed 
the highest nAb titers to the infecting serotype and lower FRNT50 
values to heterologous DENV serotypes (Figure 2A). However, 
nAb titers to heterologous DENV strains were consistently higher 
than the FRNT50 to ZIKV (Figure 2A). A peak in nAb titers for 
DENV and ZIKV was observed at the convalescent phase, and 
FRNT50 titers were relatively stable from 3 to 18 months after in-
fection. Similarly, individuals with secondary DENV infections 
showed the highest nAb titers to the DENV serotypes, although 
not necessarily the secondary infecting serotype, and the low-
est titers to ZIKV (Figure 2B). The kinetics of nAb responses in 
secondary dengue cases were comparable to those for primary 
dengue cases, with a peak in FRNT50 titers during the convales-
cent phase and stabler titers from 3 to 18 months after infection, 
although there was more-gradual antibody waning than in pri-
mary cases between 3 and 18 months. Primary and secondary 
dengue cases had similar levels of nAb titers to ZIKV over time.
To examine the kinetics of the nAb response along a longer 
time frame, we evaluated longitudinal annual samples from 
children with secondary DENV infections in our communi-
ty-based cohort study. Overall, these revealed the same trend, 
in that the highest titers were against the first infecting DENV 
serotype, which in most cases was DENV2, and the next highest 
titers were against the infecting serotype, followed by the other 
heterologous DENV serotypes and ZIKV (Figure  2C). Anti-
DENV nAb titers, as well as low levels of cross-reactivity against 
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Figure 1.  Longitudinal neutralizing antibody responses against dengue virus serotypes 1–4 (DENV1–4) and Zika virus (ZIKV) in samples obtained after ZIKV infection. The 
50% focus reduction neutralization test titer (FRNT50) for reverse-transcription polymerase chain reaction–confirmed ZIKV cases without (n = 10; A) or with (n = 7; B) evidence 
of prior DENV infection. Plasma samples obtained during the acute and convalescent (Conv) phases and 3 and 6 months after infection were evaluated by focus reduction 
neutralizing testing against all 4 DENV serotypes (Nicaraguan DENV1–4) and a Nicaraguan ZIKV isolate. All samples were processed in duplicate. Data for each sample set 
are geometric means ± standard deviations.
Antigenic Cartography Places ZIKV Outside the DENV Serocomplex
To estimate the antigenic relationships among DENV1–4 and 
ZIKV, we used antigenic cartography [32] to analyze neutral-
ization titers in plasma collected after primary DENV1–3 
and ZIKV infection from participants in the Nicaraguan hos-
pital-based study. Each neutralization titer was treated as a 
measure of distance between a plasma sample and virus, and 
simultaneous fitting of these distances produced an antigenic 
map. In the acute phase, DENV1–4 and ZIKV formed a single 
cluster (Figure  3A), but ZIKV separated from the DENV1–4 
cluster by the convalescent phase, and this is maintained out to 
6 months after infection (Figure 3B).
ZIKV Cross-neutralization Is Variable and Inferior to Heterologous DENV 
Neutralization in Plasma From Sri Lankan Subjects
To investigate the magnitude and kinetics of cross-neutraliz-
ing antibody responses to ZIKV following DENV infection in 
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Figure 2. Longitudinal neutralizing antibody responses against dengue virus serotypes 1–4 (DENV1–4) and Zika virus (ZIKV) after primary and secondary DENV infections 
among participants in the Nicaraguan hospital and cohort studies. A and B, Longitudinal plasma samples from primary (n = 5/serotype; A) and secondary (n = 5/serotype; B) 
dengue cases from the Nicaraguan hospital study, collected during the acute and convalescent phases and 3, 6, 12, and 18 months after infection. C, Longitudinal samples 
from the Nicaraguan cohort study, collected 1, 2 and 3 years after secondary infection with DENV1 (n = 4), DENV2 (n = 4), DENV3 (n = 3), and DENV4 (n = 3). Focus reduction 
neutralizing testing was performed against Nicaraguan DENV1–4 and ZIKV strains, and the 50% focus reduction neutralization test titer (FRNT50) was calculated and plotted. 
All samples were processed in duplicate. Data are geometric means ± standard deviations.
specimens from 2 sources in Sri Lanka (Table 1, Supplementary 
Table 1). From a community-based study of dengue conducted 
in 2008–2010 [26], we selected 12 subjects (6 with primary and 
6 with secondary DENV infections) who experienced a labora-
tory-confirmed, symptomatic DENV infection and had at least 
1 additional specimen available after incident DENV infection; 
the total number of samples varied depending on the basis of 
how many febrile episodes a child reported. From a Sri Lankan 
hospital-based study conducted in 2014, we selected 13 sub-
jects (7 with primary and 6 with secondary DENV infections), 
from whom convalescent-phase blood samples collected be-
tween 11 and 77 days after infection were available.
We grouped specimens tested by primary versus secondary 
DENV infection and time after symptom onset. Neutralization 
profiles (ie, FRNT50 values) to each virus at each time point are 
shown in Supplementary Table 1. In primary cases (Figure 4A), 
DENV1 was the most common infecting serotype, reflected 
in the higher neutralization titers to DENV1. The FRNT50 for 
DENV2–4 clustered at averages below those for DENV1 at each 
time point, while the ZIKV FRNT50 was approximately 10-fold 
lower than the DENV1 FRNT50. ZIKV neutralization persisted 
beyond 120 days after infection (range, 128–217 days) at sub-
stantial levels but were subordinate to DENV titers.
In secondary DENV infections (Figure  4B), ZIKV FRNT50 
titers were again the lowest of all groups. ZIKV cross-neutral-
izing titers rose later during the convalescent phase (range, 
31–90  days after infection) among secondary cases to levels 
approximating the mean FRNT50 of several DENV serotypes. 
At time points >120 days after infection (range, 123–202 days) 
in secondary cases, the mean FRNT50 for ZIKV declined mark-
edly and began to further separate from that of the DENV sero-
types. Thus, ZIKV cross-neutralization is detected after primary 
and secondary DENV cases, but typically with an FRNT50 at 
least 4-fold lower than to the infecting DENV serotype. Notably, 
most Sri Lankan hospital samples were not tested beyond a dilu-
tion of 1:1280, and many DENV1–4 FRNT50 values are >1:1280; 
thus, the difference in the magnitude of ZIKV versus DENV 











Figure 3. Antigenic relationships among dengue virus serotypes 1–4 (DENV1–4) and Zika virus (ZIKV), based on neutralizing antibody titers in plasma from primary DENV 
and ZIKV infections. Antigenic maps were generated by fitting 50% focus reduction neutralization test titers (FRNT50) for primary DENV and ZIKV infection plasma (light gray 
diamonds) from the Nicaraguan hospital-based study against DENV1–4 and ZIKV (colored circles) as distances in Euclidean space. Each grid-square corresponds to a two-
fold dilution in the FRNT50. Arrows show shifts in antigenic relationships between DENV1–4 and ZIKV Nicaraguan viruses, based on how they were recognized by plasma 
specimens collected at each time point after infection in relation to the next time point: (A) acute; (B) convalescent; (C) 3 months, and (D) 6 months after infection.
Transient Cross-neutralization of ZIKV Following DENV Infections 
Observed in a Thai Cohort
In a third country, we studied samples collected from Thai 
children (ages 6–14  years) admitted to the hospital with 
acute DENV infection during 2001–2003, when ZIKV was 
not reported in the area. Samples were collected on each 
day after hospital admission and at convalescent-phase time 
points of 2 weeks, 2 months, and 6 months following discharge 
(Table 1). Neutralization of DENV2 and ZIKV was measured 
in plasma samples from 5 children with secondary DENV2 
infection (Figure  5A, Supplementary Figure  2 and Table  2). 
In general, neutralization titers for both DENV and ZIKV 
peaked between day 0 and day 14 and declined thereafter. 
Five of 5 cases showed DENV neutralization (FRNT50 > 50% 
at a plasma dilution of 1:50), which was maintained until the 
6-month time point. Five of 6 cases also showed neutralization 
of ZIKV at early time points, but this decayed more rapidly
than the titers to DENV at 6 months. To validate these findings 
in a larger sample set representing infection by all 4 DENV
serotypes, 15 additional secondary DENV cases were tested
(Supplementary Table 3). These again showed strong neutral-
ization of all DENV serotypes at all time points, whereas nAb
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Figure 4. Cross-neutralization of Zika virus (ZIKV) following dengue virus (DENV) infection in Sri Lanka. 50% focus reduction neutralization test titers (FRNT50) were deter-
mined for DENV1–4 and ZIKV. Samples were grouped by time after laboratory-confirmed DENV infection and by primary (A) and secondary (B) DENV infection. Points are 
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Figure 5. Longitudinal neutralizing antibody responses to dengue virus (DENV) and Zika virus (ZIKV) from a Thai hospital study. A, Mean 50% focus reduction neutralization 
titers (FRNT50) to infecting DENV serotype (DENV2) and ZIKV strain PF13 of plasma specimens from subjects with secondary DENV infection (n = 5), during the course of acute 
infection, at the convalescent phase (2 weeks after infection), and at 2 and 6 months after infection. Data are presented as FRNT50 and representative of 1 experiment with 
5 samples. B, Mean FRNT50 against DENV1–4 and ZIKV strain PF13 among longitudinal specimens from 15 Thai subjects with secondary infection by any DENV serotype. 
Data are means ± standard deviations.
DENV-Immune Plasma Transiently Enhances DENV and ZIKV Infection 
In Vitro
Finally, we found that DENV2-immune plasma promoted ADE 
of both DENV and ZIKV infection in vitro at a similar peak 
enhancement titer, although the magnitude of enhancement 
was greater for DENV2 (Supplementary Figure 3).
DISCUSSION
In this study, we characterized the nAb response against DENV 
and ZIKV over time following primary and secondary DENV 
infections and drew 2 main conclusions: (1) cross-neutraliz-
ing antibody responses to ZIKV are consistently detected after 
DENV infection, but they occur at magnitudes notably less than 
to the infecting DENV serotype and generally less than to het-
erologous DENV serotypes, and (2) the magnitude and kinet-
ics of ZIKV nAb responses are unaffected by previous DENV 
infection. Both findings are consistent with ZIKV and DENV 
belonging to a distinct serocomplex.
Across multiple well-characterized DENV infection cohorts 
representing populations in Latin America and Asia, we con-
sistently observed cross-neutralizing activity against ZIKV, 
but ZIKV FRNT50 values tended to be 4–10-fold lower than 
DENV FRNT50 values. Cross-neutralization to ZIKV variably 
declines over time and is maintained at low levels in children 
for months to years after infection. We have previously seen 
that high levels of ZIKV cross-neutralizing antibodies are not 
maintained into the late convalescent phase (ie, ≥6  months 
after infection) in DENV-infected travelers [20], raising the 
possibility that ongoing DENV exposure in regions of ende-
micity may drive maintenance of cross-neutralization of ZIKV 
following DENV infection [15]. Most studies reporting strong 
cross-neutralization between ZIKV and DENV have used early 
convalescent-phase sera [8] or mAbs derived from plasma blasts 
obtained at very early time points after DENV infection [18, 
19]. Using antigenic maps, we show that DENV1–4 and ZIKV 
group closely when plasma specimens from the acute phase 
of primary DENV and ZIKV infection are analyzed; however, 
by the convalescent phase and out to 6 months after infection, 
DENV1–4 group as a serocomplex, with ZIKV clearly outside 
of the DENV antigenic cluster.
Overall, it appears that ZIKV–cross-neutralizing antibodies 
are frequently induced by DENV infection at a fraction of the 
magnitude of DENV-neutralizing antibodies, with anti-ZIKV 
titers reaching a steady-state level by 6–12 months. Furthermore, 
neutralization antibody assays can distinguish ZIKV from 
DENV infections when all viruses are analyzed simultaneously, 
particularly if relative titers of ZIKV versus DENV serotypes, 
rather than specific cutoffs for positivity, are considered [33], 
and thus may be useful in surveillance, research, and potentially 
some clinical settings outside of the acute phase of illness [20].
One assumption is that none of the subjects with dengue in-
cluded in the study were infected by ZIKV. While it is plausible 
that Zika in Asia is grossly underreported owing to a high rate 
of asymptomatic infections or attribution of Zika cases to other 
causes of acute febrile illness, such as dengue [6, 34, 35], this 
is highly unlikely in our study. Samples from Asian subjects 
did not exhibit high FRNT50 values at the earliest time points 
interrogated after DENV infection, nor did they display mainte-
nance of high ZIKV FRNT50 titers into the convalescent phase, 
which would be expected after a true prior ZIKV infection 
[12, 13]. The samples from Nicaraguan patients with dengue 
were collected years before ZIKV was reported or projected to 
be circulating in Central America [36].
The neutralization assay has been an important tool in flavi-
virology, although variations in titer between laboratories have 
been recognized [37]. Here we observed some differences in 
overall titer magnitude but reached similar conclusions across 
the 3 sites. This variation may be due to unique features of study 
populations or to details such as the virus strain used in the 
assay, DENV infection order, intensity of local transmission, 
and strain of DENV exposure, which were not systematically 
analyzed here.
The phenomenon of ADE, whereby cross-reactive non-
neutralizing antibodies facilitate infection of FcγR-bearing cells 
and lead to higher levels of viremia and more-severe disease 
manifestations, is a well-established concept in the dengue field 
[13, 38, 39] and has recently been established in human popu-
lations [40]. Although clear evidence of enhancement of ZIKV 
infection in DENV-immune humans is still lacking [41], it 
remains a major concern. While DENV and other flaviviruses 
are readily enhanced by antibodies in cell culture ADE assays 
with FcγR-bearing cell lines, such assays have not been useful 
for predicting severe DENV disease in people [42]. Here, we 
observed that plasma from  Thai individuals who had recov-
ered from DENV2 infections enhanced DENV2 to a greater 
degree  than ZIKV in cell culture assays, further highlighting 
the challenges of extrapolating the human flavivirus disease risk 
from findings of in vitro ADE assays. The enhancing activity 
peaked during the acute and convalescent phases and declined 
thereafter, mirroring the curve of neutralizing antibody profiles.
Alternatively, ZIKV cross-neutralizing antibodies elicited by 
DENV may mitigate ZIKV infection, in line with claims that 
a single vaccine against DENV1–4 and ZIKV could be devel-
oped [8, 12, 18]. Preinfection nAb titers have been associated 
with a decreased probability of symptomatic secondary DENV 
infection [15, 27], and nAb correlates of protection exist for 
other flavivirus infections [43]. However, no specific correlate 
of protection has been identified for DENV or ZIKV, and many 
individuals who seroconverted, based on neutralization test-
ing, remained susceptible to DENV infection in vaccine studies 
[44, 45]. Interestingly, DENV-immune nonhuman primates are 
readily infected with ZIKV, with no observation of enhance-
ment or protection [46, 47]. Ongoing cohort studies relating the 
known sequence and timing of DENV infections or prevalent 
DENV serostatus to ZIKV infection outcome will help address 
these critical questions.
Since 2015, many individuals in Latin America have expe-
rienced ZIKV as a primary or secondary flavivirus infection, 
raising the question of how ZIKV infection will affect immu-
nity to DENV. A dramatic reduction in dengue cases through-
out Latin America was observed in 2017 [48], suggesting 
that ZIKV infection may induce at least temporary immune 
cross-protection from DENV. Our data demonstrate that ZIKV 
infection clearly elicits cross-neutralizing antibodies to DENV 
and may boost DENV FRNT50 values in a DENV-immune host. 
Whether higher or lower rates of DENV infection occur among 
ZIKV-immune individuals will be determined in longitudinal 
cohort studies. Interestingly, we found that the magnitude of 
the anti-ZIKV nAb titer was similar regardless of prior DENV 
infection, which may be inconsistent with recent reports 
[49, 50] that prior DENV infection (at least by certain sero-
types) may potentiate the nAb response to ZIKV. We also 
noted that nAb titers to ZIKV after ZIKV infection were 
higher than nAb titers to the infecting DENV serotype after 
DENV infection.
Overall, ZIKV appears to be antigenically related but distinct 
from the DENV serotypes. Our study provides a framework for 
comprehensive assessment of the serologic immune responses to 
multiple flaviviruses that is needed to inform vaccine development 
and epidemiologic studies aimed at reducing the burden of dis-
ease caused by these important pathogens in areas of endemicity.
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